Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Following the wind down of its R&D arm, Theravance will generate revenue from two partnered, commercialised assets.
04 March 2026
04 March 2026
Following the wind down of its R&D arm, Theravance will generate revenue from two partnered, commercialised assets.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.